Composition and method for modulating an inflammatory response

Abstract

The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LTβR) modulators, which activate or inhibit LTβR signaling. LTβR modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LTβR complex proteins that act as LTβR activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LTβR, its ligands, LIGHT and LTβ1α2, or its intracellular binding partners, that function to regulate LTβR signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LTβR signaling is provided.

1 .- 41 . (canceled) 
     
     
         42 . A method of identifying a modulator of a lymphotoxin beta receptor (LTβR) complex signaling pathway, the method comprising
 contacting a cell expressing an LTβR polypeptide with a test agent selected from the group consisting of a protein, a nucleic acid, a carbohydrate, and a small molecule;   determining whether the test agent modulates activity or expression of a Smac polypeptide in said cell; and   further determining whether a test agent that modulates activity or expression of a Smac polypeptide directly interferes with LTβR-ligand binding,   wherein interference with LTβR-ligand binding identifies said test agent as a modulator of a lymphotoxin beta receptor (LTβR) complex signaling pathway.   
     
     
         43 . The method of  claim 42 , wherein said test agent is from a biological library. 
     
     
         44 . The method of  claim 42 , wherein said test agent is from a synthetic library. 
     
     
         45 . The method of  claim 44 , wherein said synthetic library is a solid phase library or a solution phase library. 
     
     
         46 . The method of  claim 42 , wherein said test agent is presented in solution, on a bead, on a chip, on a bacterium, on a spore, or on a phage. 
     
     
         47 . The method of  claim 42 , wherein interference with LTβR-ligand binding is identified by performing a competition assay with said test agent. 
     
     
         48 . The method of  claim 47 , wherein said LTβR-ligand binding is measured by enzyme-linked immunoadsorption assay (ELISA), radio-immunoassay (RIA), fluorescence-activated cell sorting (FACS), or BIACORE instrument. 
     
     
         49 . The method of  claim 42 , further comprising determining whether the test agent modulates mitochondrial-mediated apoptosis in said cell. 
     
     
         50 . The method of  claim 42 , wherein said LTβR ligand is a LIGHT polypeptide complex. 
     
     
         51 . The method of  claim 42 , wherein said LTβR ligand is a Ltα1β2 polypeptide complex. 
     
     
         52 . The method of  claim 42 , wherein said LTβR complex comprises LTβR, TRAF3, TRAF2, cIAP1, and Smac polypeptides. 
     
     
         53 . The method of  claim 42 , wherein said modulation is inhibition of the LTβR complex signaling pathway. 
     
     
         54 . The method of  claim 42 , wherein said modulation is enhancement of the LTβR complex signaling pathway. 
     
     
         55 . A method of identifying a modulator of a lymphotoxin beta receptor (LTβR) complex signaling pathway, the method comprising
 contacting a cell expressing an LTβR with a test agent selected from the group consisting of a protein, a nucleic acid, a carbohydrate, and a small molecule;   determining whether the test agent modulates activity or expression of a cIAP1 polypeptide in said cell; and   further determining whether a test agent that modulates activity or expression of a cIAP1 polypeptide directly interferes with LTβR-ligand binding,   wherein interference with LTβR-ligand binding identifies said test agent as a modulator of a lymphotoxin beta receptor (LTβR) complex signaling pathway.   
     
     
         56 . The method of  claim 55 , wherein said test agent is from a biological library. 
     
     
         57 . The method of  claim 55 , wherein said test agent is from a synthetic library. 
     
     
         58 . The method of  claim 57 , wherein said synthetic library is a solid phase library or a solution phase library. 
     
     
         59 . The method of  claim 55 , wherein said test agent is presented in solution, on a bead, on a chip, on a bacterium, on a spore, or on a phage. 
     
     
         60 . The method of claim  14 , wherein interference with LTβR-ligand binding is identified by performing a competition assay with said test agent. 
     
     
         61 . The method of  claim 60 , wherein said LTβR-ligand binding is measured by enzyme-linked immunoadsorption assay (ELISA), radio-immunoassay (RIA), fluorescence-activated cell sorting (FACS), or BIACORE instrument. 
     
     
         62 . The method of  claim 55 , further comprising determining whether the test agent modulates mitochondrial-mediated apoptosis in said cell. 
     
     
         63 . The method of  claim 55 , wherein said LTβR ligand is a LIGHT polypeptide complex. 
     
     
         64 . The method of  claim 55 , wherein said LTβR ligand is a Ltα1β2 polypeptide complex. 
     
     
         65 . The method of  claim 55 , wherein said LTβR complex comprises LTβR, TRAF3, TRAF2, cIAP1, and Smac polypeptides. 
     
     
         66 . The method of  claim 55 , wherein said modulation is inhibition of the LTβR complex signaling pathway. 
     
     
         67 . The method of  claim 55 , wherein said modulation is enhancement of the LTβR complex signaling pathway. 
     
     
         68 . A method of identifying a modulator of a lymphotoxin beta receptor (LTβR) complex signaling pathway, the method comprising
 contacting a cell expressing an LTβR with a test agent selected from the group consisting of a protein, a nucleic acid, a carbohydrate, and a small molecule;   determining whether the test agent modulates activity or expression of a TRAF2 polypeptide in said cell; and   further determining whether a test agent that modulates activity or expression of a TRAF2 polypeptide directly interferes with LTβR-ligand binding,   wherein interference with LTβR-ligand binding identifies said test agent as a modulator of a lymphotoxin beta receptor (LTβR) complex signaling pathway.   
     
     
         69 . The method of  claim 68 , wherein said test agent is from a biological library. 
     
     
         70 . The method of  claim 68 , wherein said test agent is from a synthetic library. 
     
     
         71 . The method of  claim 70 , wherein said synthetic library is a solid phase library or a solution phase library. 
     
     
         72 . The method of  claim 68 , wherein said test agent is presented in solution, on a bead, on a chip, on a bacterium, on a spore, or on a phage. 
     
     
         73 . The method of  claim 68 , wherein interference with LTβR-ligand binding is identified by performing a competition assay with said test agent. 
     
     
         74 . The method of  claim 73 , wherein said LTβR-ligand binding is measured by enzyme-linked immunoadsorption assay (ELISA), radio-immunoassay (RIA), fluorescence-activated cell sorting (FACS), or BIACORE instrument. 
     
     
         75 . The method of  claim 68 , further comprising determining whether the test agent modulates mitochondrial-mediated apoptosis in said cell. 
     
     
         76 . The method of  claim 68 , wherein said LTβR ligand is a LIGHT polypeptide complex. 
     
     
         77 . The method of  claim 68 , wherein said LTβR ligand is a Ltα1β2 polypeptide complex. 
     
     
         78 . The method of  claim 68 , wherein said LTβR complex comprises LTβR, TRAF3, TRAF2, cIAP1, and Smac polypeptides. 
     
     
         79 . The method of  claim 68 , wherein said modulation is inhibition of the LTβR complex signaling pathway. 
     
     
         80 . The method of  claim 68 , wherein said modulation is enhancement of the LTβR complex signaling pathway. 
     
     
         81 . A method of identifying a modulator of a lymphotoxin beta receptor (LTβR) complex signaling pathway, the method comprising
 contacting a cell expressing an LTβR polypeptide with a test agent selected from the group consisting of a protein, a nucleic acid, a carbohydrate, and a small molecule;   determining whether the test agent modulates activity or expression of an ERH polypeptide in said cell; and   further determining whether a test agent that modulates activity or expression of an ERH polypeptide modulates LTβR-ligand binding,   wherein interference with LTβR-ligand binding identifies said test agent as a modulator of a lymphotoxin beta receptor (LTβR) complex signaling pathway.   
     
     
         82 . The method of  claim 81 , wherein said test agent is from a biological library. 
     
     
         83 . The method of  claim 81 , wherein said test agent is from a synthetic library. 
     
     
         84 . The method of  claim 83 , wherein said synthetic library is a solid phase library or a solution phase library. 
     
     
         85 . The method of  claim 81 , wherein said test agent is presented in solution, on a bead, on a chip, on a bacterium, on a spore, or on a phage. 
     
     
         86 . The method of  claim 81 , wherein interference with LTβR-ligand binding is identified by performing a competition assay with said test agent. 
     
     
         87 . The method of  claim 86 , wherein said LTβR-ligand binding is measured by enzyme-linked immunoadsorption assay (ELISA), radio-immunoassay (RIA), fluorescence-activated cell sorting (FACS), or BIACORE instrument. 
     
     
         88 . The method of  claim 81 , further comprising determining whether the test agent modulates mitochondrial-mediated apoptosis in said cell. 
     
     
         89 . The method of  claim 81 , wherein said LTβR ligand is a LIGHT polypeptide complex. 
     
     
         90 . The method of  claim 81 , wherein said LTβR ligand is a Ltα1β2 polypeptide complex. 
     
     
         91 . The method of  claim 81 , wherein said LTβR complex comprises LTβR, TRAF3, TRAF2, cIAP1, and Smac polypeptides. 
     
     
         92 . The method of  claim 81 , wherein said modulation is inhibition of the LTβR complex signaling pathway. 
     
     
         93 . The method of  claim 81 , wherein said modulation is enhancement of the LTβR complex signaling pathway.